A novel immunotherapy combination induced remarkable regression of tumors in a mouse model of head and neck cancer.

A PET probe that detects the amino acid glutamine predicts whether tumors respond to certain targeted therapies in preclinical animal models.

The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis.

New findings shed light on how enzymes that replicate DNA skip over mutations that might cause cancer and restart DNA synthesis further away.

Vanderbilt investigators report that dysregulation of certain immune cells in the intestines may lead to inflammation and disease.

The Vanderbilt Diabetes Research and Training Center (VDRTC) is celebrating its 44th year of operation with a five-year competitive renewal of its $9 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH).

A 10-year study, led by Vanderbilt University Medical Center professor of Obstetrics and Gynecology Katherine Hartmann, M.D., Ph.D., disrupts conventional wisdom that uterine fibroids cause miscarriages.